In Q3 2025, Pfizer Inc. reported quarterly revenue of $67.8 billion and net income of $19.4 billion, representing a QoQ growth rate of 14.1% and a YoY decline of -30.8%. Despite this setback, the company's operating margin came in at 25.4%, which is above the sector average of 13.6%.
Looking ahead to the future, Pfizer's growth prospects remain promising, driven by its strong pipeline and potential entry into the anti-obesity market. The recent launch of GLP-1 products has provided a positive catalyst for the company, while post-COVID recovery is also expected to contribute to growth. However, there are some concerns around trade tariffs that may impact Pfizer's performance.
From an investment perspective, Pfizer's potential for growth in the anti-obesity market makes it an attractive opportunity. The global anti-obesity drug market is projected to reach $40 billion by 2026, with a CAGR of 15%. Pfizer's GLP-1 products are well-positioned to capture a significant share of this growing market.
While there are no clear risk factors identified for Pfizer at this time, investors should keep an eye on potential trade tensions that could impact the company's operations. Additionally, Pfizer's 3-year revenue CAGR of -14.32% and 3-year profit CAGR of -26.38% suggest that the company has struggled to maintain growth in recent years.
Overall, Pfizer remains a significant player in the healthcare sector, with a strong pipeline and potential for growth in the anti-obesity market. However, investors should carefully consider the risks associated with trade tensions and the company's historical growth trends before making investment decisions.